IMI公司开发早期筛查大肠癌的新检测方法

一种新的检测方法具有检测超过半数的早期直肠癌的功能。

这种简单的检测方法能够在医生的办公室内进行，用于筛查早期大肠癌和直肠癌。近期的资料显示：这种叫做ColorectAlert的检测方法的假阳性比例比当前最主要的筛查方法大便隐血实验要低5倍多。

ColorectAlert通过鉴别医生在常规直肠检查时候收集的粘膜样本之中的癌症相关的糖来进行检测。无需血液或者大便样本。因为样本是由医生直接收集而不是患者收集，这种检测能够为更多的患者进行筛查。绝大多数其它直肠癌的检测方法需要复杂的患者准备程序以及创伤性手术，而且常常出现非确定性的结果。

ColorectAlert是由IMI国际医疗创新公司(IMI, Toronto, Canada)研制开发的。 IMI公司规划与临床事务部经理Micheal Evelegh博士说：“很明显，当前迫切需要患者能够负担的起的易于操作的大肠癌早期筛查方法。”该公司正在计划开展大规模、多中心的前瞻性临床试验，希望获得明确资料来支持这项筛查工具的有效性。
 
Novel Screen for Colon Cancer
 
A new test has shown the ability to detect more than half of all early-stage colorectal cancers.

The simple test can be performed in a doctor’s office to screen for early-stage cancer of the colon and rectum. Recent data show that the test, called ColorectAlert, had five times fewer false-positives than fecal occult blood tests, currently the leading method of screening.

ColorectAlert works by identifying a cancer-associated sugar in a sample of mucus collected by a doctor during a routine digital rectal exam. No blood or stool sample is needed. Since the sample is obtained directly from a doctor rather than by the patient, the test may contribute to more patient screening. Most other diagnostic tests for colorectal cancer require extensive patient preparation and an invasive procedure, while often delivering inconclusive results.

ColorectAlert was developed by IMI International Medical Innovations (IMI, Toronto, Canada). “Clearly, an affordable easy-to-use initial screen for early stage colorectal cancer is urgently needed,” stated Dr. Micheal Evelegh, head of regulatory and clinical affairs at IMI. The company is planning a major, multisite prospective trial that is expected to generate definitive data to support the test’s effectiveness as a screening tool.